Credent Connect N Care Limited
Closed13–17 Aug 2026
Updated 2026-08-21 (IST)
Business overview
Our company is a healthcare services provider engaged in delivering integrated logistics, workforce solutions, and technology-enabled support to healthcare institutions across India. We provide comprehensive operational and logistics services to diagnostic laboratories, In Vitro Diagnostics (IVD) companies, pharmaceutical companies, clinics, and other healthcare enterprises through end-to-end solutions.
Profit & Loss
Rs crore · AnnualLatest year highlighted in green. Sparklines show the trend.
| 2023-24 | 2024-25 | 2025-26 | ||
|---|---|---|---|---|
| Sales | 76 | 78 | 214 | |
| Operating Profit | 4 | 5 | 28 | |
| OPM % | 5.7% | 6.4% | 13.3% | |
| Net Profit | 3 | 2 | 18 | |
| Total Debt | 7 | 7 | 22 |
Offer structure
Total: ₹0 cr. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders.
Use of proceeds- Investment in our wholly owned subsidiary, Credent Healthcare Private Limited to meet its working capital requirement — ₹27 cr
- Investment in our wholly owned subsidiary, Credent Healthcare Private Limited to finance its capital expenditure requirements for machinery — ₹3 cr
- To meet Working Capital Requirements — ₹37 cr
- Repayment and/or repayment, in full or part, of borrowing availed by our Company — ₹6 cr
- General corporate purposes
Promoters
- Ashok Kumar Sharma — Non-Executive Director
- Karan Sharma — Whole Time Director & CFO
- Tarun Sharma — Chairman & Managing Director
- Dimple Sharma — Non-Executive Director
- Tanveen — Promoter
Strengths & risks
Company-stated strengths and disclosed risk factors from the offer document.
- Comprehensive Healthcare Ecosystem and Logistics Platform (p.122)
- Well established relationships with clients (p.122)
- Leveraging the experience of our Promoters and Directors (p.122)
- Widespread reach in domestic markets (p.122)
- We derive a significant portion of our revenue from operations from our top 10 customers with which we do not have any firm commitments. (p.25)
- Our business is dependent on diagnostic and healthcare companies, and any reduction in their testing volumes, outsourcing requirements, or adverse sector developments could materially and adversely affect our business. (p.26)
- We are exposed to risks relating to loss, damage, contamination or delay in transportation of diagnostic samples, which could result in client claims, financial liabilities and reputational harm. (p.26)
- Our business is working capital intensive and trade receivables constitute a significant portion of our current assets. (p.27)
- Our subsidiary companies has incurred losses and had a negative net worth in the past, and any future losses may adversely affect its financial condition and our consolidated results. (p.29)
Market & competition
We operate in a fragmented and evolving healthcare logistics and support services market in which there are currently no listed companies that are directly comparable to our business model.
Future outlook
We intend to continue investing in and enhancing our technological capabilities to support healthcare companies with software solutions and digital tools tailored to their operational needs. We plan to deepen our engagement with existing clients by expanding the range of services offered, including warehousing and distribution solutions and healthcare specific long-distance logistics. Concurrently, we intend to expand our presence across Tier 2 and Tier 3 cities in India, targeting regional, standalone, and smaller healthcare providers.
Never miss an IPO like this
Every upcoming IPO analysed — subscription, GMP and a DRHP breakdown — in your inbox, free. One email when each one opens.
Sources & method
Subscription and issue data come from the NSE and BSE exchange feeds, with the third-party aggregator, clearly labelled, where an exchange feed is unreachable. DRHP analysis is extracted from the offer document itself, every figure cited to its page. Each figure on the page carries its source and its timestamp.
Grey-market premium (GMP) is unregulated.
Every GMP figure is a self-reported grey-market estimate — no exchange, regulator or clearing body records or audits it, and there is no settlement guarantee or recourse. Shown for context only; never decide on GMP alone. New to GMP? The 30-second explainer →